Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Are RAS mutations predictive markers of resistance to standard chemotherapy?

Nature reviews. Clinical oncology - 1 Sept 2009

Loriot Yohann, Mordant Pierre, Deutsch Eric, Olaussen Ken André, Soria Jean-Charles

Abstract excerpt

KRAS mutations may be predictive of resistance to anti-EGFR monoclonal-based therapy in patients with colorectal cancer (CRC). Screening for KRAS mutations in patients with CRC and non-small-cell lung cancer (NSCLC) may provide additional information on optimizing treatment options with targeted therapies. Only limited studies, however, have assessed the predictive value of KRAS mutations in response to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carboplatin
Share to Cisplatin
Share to Clinical Trials, Phase III as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Drug Therapy

Share to Etoposide

Share to Genes, ras

Share to Mitomycin

Source

Identifiers

PMID: 19597509
DOI: 10.1038/nrclinonc.2009.106

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Are RAS mutations predictive markers of resistance to standard chemotherapy?PMID 19597509Read ↗

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?Semantic proximity Read ↗

KRAS mutations as prognostic and predictive markers in non-small cell lung cancer.Semantic proximity Read ↗

KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.Semantic proximity Read ↗

KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study.Semantic proximity Read ↗

KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue.Semantic proximity Read ↗

Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies.Semantic proximity Read ↗

RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer.Semantic proximity Read ↗

Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma.Semantic proximity Read ↗

[Prognostic role of KRAS mutation in colorectal cancer].Semantic proximity Read ↗

Genetics: Predictive value of KRAS mutations in chemoresistant CRC.Semantic proximity Read ↗

KRAS status predicts response to cetuximab for metastatic colorectal cancer.Semantic proximity Read ↗

Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.